cysteine has been researched along with Parkinson Disease, Secondary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colín-González, AL; Galván-Arzate, S; García, E; Heras, Y; Maldonado, PD; Santamaría, A; Santana-Martínez, R; Silva-Islas, CA; Sotelo, J | 1 |
| Charlton, CG; Lamango, NS | 1 |
2 other study(ies) available for cysteine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
S-allyl cysteine protects against MPTP-induced striatal and nigral oxidative neurotoxicity in mice: participation of Nrf2.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cell Nucleus; Corpus Striatum; Cysteine; Dopamine; Drug Evaluation, Preclinical; Heme Oxygenase-1; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Neuroprotective Agents; NF-E2-Related Factor 2; Oxidative Stress; Parkinson Disease, Secondary; Substantia Nigra; Superoxide Dismutase; Superoxide Dismutase-1; Tyrosine 3-Monooxygenase | 2014 |
Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Chromatography, Gel; Cysteine; Freeze Drying; Male; Methylation; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Stereotyped Behavior; Sympathectomy, Chemical; Tremor | 2000 |